

**SUVEN LIFE SCIENCES LTD**

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE &amp; CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2022 &amp; UNAUDITED STANDALONE &amp; CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2022

Rs. In Lakhs						
PART - I		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2022	31/12/2021	31/03/2021	31/03/2022	31/03/2021
		Refer note.7	Un-Audited	Refer note.7	Audited	Audited
		(1)	(2)	(3)	(4)	(5)
1	<b>Income</b>					
	Revenue from operations	422.13	443.29	155.71	1,184.43	1,347.83
	Other Income	11.81	14.09	132.31	531.71	775.37
	<b>Total income</b>	<b>433.94</b>	<b>457.38</b>	<b>288.02</b>	<b>1,716.14</b>	<b>2,123.20</b>
2	<b>Expenses</b>					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	505.67	410.44	321.77	1,746.40	1,528.50
	d) Finance costs	9.78	12.96	17.59	53.01	81.54
	e) Depreciation and amortisation expense	110.23	122.22	106.56	439.32	434.62
	f) Manufacturing Expenses	-	-	-	-	-
	g) R & D Expenses	402.53	564.39	589.96	2,453.42	2,517.04
	h) Other Expenses	261.10	169.29	98.35	648.85	356.99
	<b>Total expenses</b>	<b>1,289.31</b>	<b>1,279.30</b>	<b>1,134.23</b>	<b>5,341.00</b>	<b>4,918.69</b>
3	Profit before exceptional items & Tax (1-2)	(855.37)	(821.92)	(846.21)	(3,624.86)	(2,795.49)
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	(855.37)	(821.92)	(846.21)	(3,624.86)	(2,795.49)
6	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	4.58	-	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(855.37)	(821.92)	(850.79)	(3,624.86)	(2,263.21)
8	<b>Other Comprehensive Income</b>					
8.a	(i) Items that will not be reclassified to profit or loss	20.31	(11.78)	(13.09)	(15.05)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	4.58	-	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>20.31</b>	<b>(11.78)</b>	<b>(8.51)</b>	<b>(15.05)</b>	<b>(30.67)</b>
9	Total Comprehensive Income for the period (7+8)	(835.06)	(833.70)	(859.30)	(3,639.91)	(2,293.88)
10	Paid-up equity share capital	1,453.82	1,272.82	1,272.82	1,453.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity				46,143.89	35,200.63
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic (Based on weighted average no.of shares)	(0.67)	(0.65)	(0.67)	(2.84)	(1.78)
	b) Diluted(Based on weighted average no.of shares)	(0.67)	(0.65)	(0.67)	(2.84)	(1.78)
		(not annualised)	(not annualised)	(not annualised)		



PART - I		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2022	31/12/2021	31/03/2021	31/03/2022	31/03/2021
		Refer note.7	Un-Audited	Refer note.7	Audited	Audited
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	422.13	443.29	155.71	1,184.43	1,347.83
	Other Income	11.82	14.09	132.31	531.71	775.37
	<b>Total income</b>	<b>433.95</b>	<b>457.38</b>	<b>288.02</b>	<b>1,716.14</b>	<b>2,123.20</b>
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	576.19	506.01	417.05	2,102.08	1,852.75
	d) Finance costs	9.78	12.96	24.19	53.01	81.54
	e) Depreciation and amortisation expense	110.23	122.23	106.56	439.32	434.62
	f) Manufacturing Expenses	-	-	-	-	-
	g) R & D Expenses	1,545.75	3,007.31	1,795.58	10,636.75	7,102.73
	h) Other Expenses	271.81	177.90	101.30	684.49	398.96
	<b>Total expenses</b>	<b>2,513.76</b>	<b>3,826.41</b>	<b>2,444.68</b>	<b>13,915.65</b>	<b>9,870.60</b>
3	Profit before exceptional items , Tax (1-2)	(2,079.81)	(3,369.03)	(2,156.66)	(12,199.51)	(7,747.40)
4	Exceptional Items- (Ref Note:7)	-	-	-	-	-
5	Profit before Tax (3-4)	(2,079.81)	(3,369.03)	(2,156.66)	(12,199.51)	(7,747.40)
6	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	4.58	-	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(2,079.81)	(3,369.03)	(2,161.24)	(12,199.51)	(7,215.12)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	20.31	(11.78)	(13.09)	(15.05)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	4.58	-	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>20.31</b>	<b>(11.78)</b>	<b>(8.51)</b>	<b>(15.05)</b>	<b>(30.67)</b>
9	Total Comprehensive Income for the period ( 7+ 8)	(2,059.50)	(3,380.81)	(2,169.75)	(12,214.56)	(7,245.79)
10	Paid-up equity share capital Face Value of the Share	1,453.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,453.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	8,160.71	5,835.74
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic (Based on weighted average no.of shares)	(1.63)	(2.65)	(1.70)	(9.57)	(5.67)
	b) Diluted(Based on weighted average no.of shares)	(1.63)	(2.65)	(1.70)	(9.57)	(5.67)
		(not annualised)	(not annualised)	(not annualised)		



**NOTES:-**

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 07, 2022. The results for the year ended March 31, 2022 has been audited and for the quarter ended March 31, 2022 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc

4) The COVID-19 did not have impact on the business and research operations in India. However, we are foreseeing certain delays in enrollment of ongoing phase 2 clinical studies conducted in our subsidiary, Suven Neurosciences, Inc USA.

5) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

6) During the year ended 31-03-2022 the Board of Directors in its meeting held on 28th March 2022 has approved the conversion of 1,81,00,000 share warrants into equal number of equity shares to promoter group.

7) The figures for the current quarter and quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2022 and March 31, 2021, respectively and published year to date figures upto 3rd quarter ended 31st December 2021 and 31st December 2020, respectively, regrouped as necessary.

Place : Hyderabad  
Date : May 7, 2022



For SUVEN LIFE SCIENCES LTD

  
VENKAT JASTI  
Chairman & CEO  
DIN: 00278028





# SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

## Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2022	31/03/2021	31/03/2022	31/03/2021
<b>A ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	3,508.77	1,774.48	3,508.77	1,774.48
(b) Capital Work-in-Progress	355.05	477.40	355.05	477.40
(c) Other Intangible Assets	22.46	13.60	22.46	13.60
(d) Right of use Assets	225.23	308.18	225.23	308.18
(e) Financial Assets				
I. Investments	38,069.16	29,502.55	-	-
II. Loans	-	-	-	-
(f) Other Non-current Assets	32.50	-	32.50	-
<b>Total Non-Current assets</b>	<b>42,213.17</b>	<b>32,076.21</b>	<b>4,144.01</b>	<b>2,573.66</b>
<b>2 Current assets</b>				
<b>Inventories</b>	<b>2.24</b>	<b>14.15</b>	<b>2.24</b>	<b>14.15</b>
(a) Financial Assets				
I. Investments	4,516.20	8.57	4,516.20	8.57
II. Trade Receivables	129.79	176.19	129.79	176.19
III. Cash and Cash equivalents	290.04	129.07	527.35	934.82
IV. Bank balances other than (III) above	24.73	3,730.12	24.73	3,730.12
V. Loans	-	4,144.87	-	4,144.87
(b) Current Tax asset (net)	586.80	534.78	586.80	534.78
(c) Other current assets	872.34	724.64	872.34	724.64
<b>Total Current assets</b>	<b>6,422.14</b>	<b>9,462.39</b>	<b>6,659.45</b>	<b>10,268.14</b>
<b>TOTAL - ASSETS</b>	<b>48,635.31</b>	<b>41,538.60</b>	<b>10,803.46</b>	<b>12,841.80</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 EQUITY</b>				
(a) Equity Share Capital	1,453.82	1,272.82	1,453.82	1,272.82
(b) Warrants	-	3,692.00	-	3,692.00
(c) Other Equity	46,143.90	35,200.64	8,160.71	5,835.74
<b>Total Equity</b>	<b>47,597.72</b>	<b>40,165.46</b>	<b>9,614.53</b>	<b>10,800.56</b>
<b>2 LIABILITIES</b>				
(a) Financial Liabilities				
I. Lease Liabilities	157.30	232.60	157.30	232.60
II. Borrowings	-	39.25	-	39.25
(b) Provisions	200.16	172.87	200.16	172.87
(c) Other non current liabilities	-	5.56	-	5.56
<b>Total non-current liabilities</b>	<b>357.46</b>	<b>450.28</b>	<b>357.46</b>	<b>450.28</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
I. Lease Liabilities	115.13	110.11	115.13	110.11
II. Borrowings	48.43	94.40	48.43	94.40
III. Trade payables				
a) To Micro & Small Enterprises	27.32	19.61	27.32	19.61
b) Other than Micro & Small Enterprises	171.34	279.95	171.34	279.95
III. Other Financial Liabilities	169.09	268.15	320.43	936.25
(b) Other Current liabilities	60.20	72.30	60.20	72.30
(c) Provision Employee benefits	88.62	78.34	88.62	78.34
<b>Total - Current liabilities</b>	<b>680.13</b>	<b>922.86</b>	<b>831.47</b>	<b>1,590.96</b>
<b>Total Liabilities</b>	<b>1,037.59</b>	<b>1,373.14</b>	<b>1,188.93</b>	<b>2,041.24</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>48,635.31</b>	<b>41,538.60</b>	<b>10,803.46</b>	<b>12,841.80</b>

For Suven Life Sciences Ltd

Place : Hyderabad  
Date : May 7, 2022



Venkat Jasti  
Chairman & CEO

SUVEN LIFE SCIENCES LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2022

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2022	For the year ended 31st March 2021
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(3,624.86)	(2,795.50)
<b>Adjustments :</b>		
Depreciation and amortisation expense	356.37	352.44
Interest Income	(111.69)	(697.91)
Finance Cost	53.01	81.54
Insurance Receipt	(371.57)	-
Gain on Unrealised Current Investment	(35.56)	(6.06)
<b>Operating profit before working capital changes</b>	<b>(3,734.30)</b>	<b>(3,065.49)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	46.40	50.86
Inventories	11.91	(14.15)
Other non current assets	50.45	82.18
Other current assets	223.87	(436.51)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(100.89)	(278.64)
Long term provisions	27.28	0.80
Other non-current liabilities	(5.56)	(41.07)
Short term provision	(4.77)	(42.11)
Other financial liabilities	(112.56)	182.43
Other current liabilities	(12.10)	7.73
<b>Cash generated from operating activities</b>	<b>(3,610.27)</b>	<b>(3,553.97)</b>
Income taxes paid (net of refunds)	52.02	114.52
<b>Net Cash flows from operating activities</b>	<b>(3,662.29)</b>	<b>(3,668.49)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(1,977.16)	(630.47)
Other non current financial assets	-	9,125.25
Other current financial assets	4,144.87	55.83
Interest received	111.69	697.91
Changes in Investments	(8,566.62)	(5,321.24)
Sale/(purchase) of mutual funds	(4,472.07)	2.43
Bank balances not considered as cash and cash equivalents	13.39	(3,688.47)
<b>Net cash flow from /( used in) investing activities</b>	<b>(10,745.90)</b>	<b>241.24</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from borrowings	(85.23)	(69.24)
Proceeds from warrant converted into Equity Shares	14,764.17	-
Proceeds from Share Warrants	-	3,692.00
Changes In Lease Liability	(70.27)	(55.66)
Finance Cost	(39.51)	(81.54)
<b>Net cash flow from /(used In) financing activities</b>	<b>14,569.16</b>	<b>3,485.56</b>
Net increase/(decrease) in cash and cash equivalents	160.97	58.31
Cash and cash equivalents as at the beginning of the year	129.07	70.76
<b>Cash and cash equivalents at the end of the year</b>	<b>290.04</b>	<b>129.07</b>
Cash and cash equivalents	290.04	129.07
<b>Balances per statement of cash flows</b>	<b>290.04</b>	<b>129.07</b>

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI  
Chairman & CEO  
DIN: 00278028

Place : Hyderabad  
Date : May 7,2022



SUVEN LIFE SCIENCES LIMITED

Consolidated Statement of Cash flows for the year ended 31st March, 2022

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2022	For the year ended 31st March 2021
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(12,199.51)	(7,747.41)
<b>Adjustments :</b>		
Depreciation and amortisation expense	356.37	352.44
Interest Income	(111.69)	(697.91)
Finance Cost	53.01	81.54
Insurance Receipt	(371.57)	-
Gain on Unrealised Current Investment	(35.56)	(6.06)
<b>Operating profit before working capital changes</b>	<b>(12,308.95)</b>	<b>(8,017.40)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	46.40	50.86
Inventories	11.91	(14.15)
Other non current assets	50.45	82.18
Other current assets	223.87	(436.51)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(100.89)	(278.64)
Long term provisions	27.28	0.80
Other non-current liabilities	(5.56)	(41.07)
Short term provision	(4.77)	(42.11)
Other financial liabilities	(629.32)	(799.53)
Other current liabilities	(12.10)	7.73
<b>Cash generated from operating activities</b>	<b>(12,701.68)</b>	<b>(9,487.85)</b>
Income taxes paid (net of refunds)	52.02	114.52
<b>Net Cash flows from operating activities</b>	<b>(12,753.70)</b>	<b>9,602.36</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(1,977.16)	(630.47)
Other non current financial assets	-	9,125.25
Other current financial assets	4,144.87	57.88
Interest received	111.69	697.91
Sale/(purchase) of mutual funds	(4,472.07)	2.43
Foreign currency translation reserve	(43.64)	19.52
Bank balances not considered as cash and cash equivalents	13.39	(3,688.47)
<b>Net cash flow from /( used in) investing activities</b>	<b>(2,222.92)</b>	<b>5,584.04</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from borrowings	(85.23)	(69.24)
Proceeds from warrant converted into Equity Shares	14,764.17	-
Proceeds from Share Warrants	-	3,692.00
Changes In Lease Liability	(70.27)	(55.66)
Finance Cost	(39.51)	(81.54)
<b>Net cash flow from /(used In) financing activities</b>	<b>14,569.16</b>	<b>3,485.56</b>
Net increase/(decrease) in cash and cash equivalents	(407.46)	(532.76)
Cash and cash equivalents as at the beginning of the year	934.82	1,467.57
<b>Cash and cash equivalents at the end of the year</b>	<b>527.36</b>	<b>934.82</b>
Cash and cash equivalents	527.36	934.82
<b>Balances per statement of cash flows</b>	<b>527.36</b>	<b>934.82</b>

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI  
Chairman & CEO  
DIN: 00278028

Place : Hyderabad

Date : May 7,2022